Blog

LOCAL PARTNERSHIPS: PREPARING TO SUPPORT SUSTAINED ACCESS AND EFFECTIVE USE OF HIV PREVENTION PRODUCTS

The success of efforts to introduce new pre-exposure prophylaxis (PrEP) methods for HIV prevention, such as the PrEP ring and injectable CAB PrEP, will also rely on local partners. That’s why one of MOSAIC’s five strategic objectives is dedicated to strengthening local partner capacity to design and implement high-quality product introduction activities and research.

Continue Reading

Blog

A NEW OPTION TO TRANSFORM HIV PREVENTION

The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.

Continue Reading

Events

WHAT’S NEXT FOR CAB PrEP?

In this webinar, we explore ongoing and completed research on CAB PrEP, learn about the recently released FDA guidance, and hear from a panel of implementers and policymakers on what is needed to advance introduction of this new HIV prevention product.

Continue Reading